Related Experiment Video
Updated: Apr 30, 2026
Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
Published on: August 13, 2021
Engineering immunostimulatory nanocarriers: TLR7-agonist conjugated poly(beta-amino ester) mRNA delivery systems
Hulya Bayraktutan1,2,3, Amr ElSherbeny1,2, Rafał J Kopiasz1,4
1Division of Molecular Therapeutics and Formulation, Boots Science Building, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK. cameron.alexander@nottingham.ac.uk.
Researchers developed a new poly(beta-amino ester) nanoparticle that delivers self-amplifying RNA (saRNA) and acts as a Toll-like receptor 7 (TLR7) adjuvant. While effective in cell lines, further development is needed to enhance its activity in primary immune cells for improved RNA vaccines.
Area of Science:
- Biotechnology
- Vaccine Development
- Nanomedicine
Background:
- Messenger RNA (mRNA) technology is crucial for vaccines and therapeutics, but requires effective delivery vectors.
- Nanoparticle carriers, like poly(beta-amino esters) (PBAEs), are promising for RNA delivery.
- Existing mRNA vaccines show short immune response durability, necessitating improved delivery systems.
Purpose of the Study:
- To develop a Toll-like receptor 7 (TLR7)-adjuvanting poly(beta-amino ester) (PBAE) nanoparticle for enhanced RNA vaccine delivery.
- To conjugate Loxoribine, a TLR7 agonist, directly to PBAE to create an adjuvanting delivery system.
- To evaluate the efficacy and safety of these novel nanoparticles for self-amplifying RNA (saRNA) delivery.
Main Methods:
- Conjugation of Loxoribine to PBAE to create an adjuvanting polymer.
- Condensation of self-amplifying RNA (saRNA) into PBAE nanoparticles (100-200 nm).
- Transfection efficiency and cytotoxicity assays in HEK293T and DC2.4 cell lines.
- Toll-like receptor (TLR) activation assays using reporter cell lines and primary immune cells.
Main Results:
- Loxoribine-conjugated PBAE efficiently condensed saRNA into nanoparticles.
- Formulations showed high transfection efficiency and good cytotoxicity profiles in model cell lines.
- Adjuvanting nanoparticles demonstrated potent TLR7 activation in reporter cells, with some synergy with saRNA.
- However, minimal activation of primary immune cells (bone marrow-derived dendritic cells) was observed.
Conclusions:
- Adjuvanted PBAE nanoparticles show potential for enhancing RNA vaccines by delivering saRNA with inherent TLR7 agonism.
- Further optimization is required to improve the nanoparticle's activity and transfection efficiency in primary immune cells.
- This study highlights a promising strategy for next-generation RNA vaccine delivery systems.
